BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

8.105 +0.005 (+0.06%)

Delayed Quote Updated: 12:08 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

April 11, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Oppenheimer Maintains Outperform Rating for BioCryst Pharmaceuticals, Lowers Price Target To $16 ↗

April 11, 2022

Oppenheimer has decided to maintain its Outperform rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) and lower its price target from $20.00 to $16.00. Shares of BioCryst Pharmaceuticals are trading down...

Via Benzinga

Why BioCryst Pharmaceuticals Stock Is Falling ↗

April 11, 2022

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Crude Oil Rises 2% ↗

April 08, 2022

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping more than 100 points on Friday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 08, 2022

Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume...

Via Benzinga

Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder ↗

April 08, 2022

Via Benzinga

Can Recent Catalysts Breakout BioCryst To New Highs? ↗

February 09, 2022

In today’s volatile markets, finding a biotech stock that isn’t purely speculative can be challenging, and yet BCRX may have what it takes.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022 ↗

April 11, 2022

Upgrades

Via Benzinga

28 Stocks Moving In Friday's Mid-Day Session ↗

April 08, 2022

Gainers Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million. TSR, Inc. (NASDAQ...

Via Benzinga

BioCryst Is On Fire: What Do Options Traders Expect Next? ↗

January 12, 2022

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) sur...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

April 08, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Mid-Day Market Update: Dow Jumps Over 200 Points; Sunshine Biopharma Shares Slide ↗

April 08, 2022

U.S. stocks traded mixed midway through trading, with the Dow Jones surging more than 200 points on Friday.

Via Benzinga

Mid-Morning Market Update: Markets Edge Lower; US Wholesale Inventories Rise 2.5% In February ↗

April 08, 2022

U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping 100 points on Friday.

Via Benzinga

Why BioCryst Pharmaceuticals Stock Is Plunging Today ↗

April 08, 2022

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading significantly lower Friday after the company paused enrollment in clinical trials with BCX9930 while it ...

Via Benzinga

Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating ↗

March 23, 2022

Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday.

Via Investor's Business Daily

BioCryst Continues To Develop A Strong Pipeline ↗

March 15, 2022

Investing in biotech stocks often comes with huge risks and rewards, as a company is dependent on its pipeline and royalty payments.

Via Talk Markets

BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates ↗

February 24, 2022

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) announced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the...

Via Benzinga

Recap: BioCryst Pharmaceuticals Q4 Earnings ↗

February 23, 2022

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the...

Via Benzinga

BioCryst Hit 15-Year Highs But What's In Store Tomorrow For Earnings? ↗

February 22, 2022

By StoryTrading BioCryst’s (NASDAQ: BCRX) stock price hit 15-year highs since our article was published on Benzinga earlier this month, but with the oral prophylactic...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts? ↗

February 09, 2022

By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for Orladeyo and $300M influx of cash from royalty deals – Potential catalysts: update on Orladeyo sales with Q4 results on...

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, Here's How Much You Would Have Today ↗

January 12, 2022

BioCryst Pharmaceuticals (NASDAQ:BCRX) has outperformed the market over the past 10 years by 5.6% on an annualized basis. Buying $1,000 In BCRX: 10 years ago, an investor could...

Via Benzinga

60 Biggest Movers From Yesterday ↗

January 11, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...

Via Benzinga

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

45 Stocks Moving In Monday's Mid-Day Session ↗

January 10, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired...

Via Benzinga

3 Stocks Insiders Are Buying ↗

November 26, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 ↗

December 10, 2021

Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE:

Via Benzinga

BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo ↗

November 22, 2021

Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals...

Via Benzinga

7 Top Growth Stocks to Buy as We Step Into November ↗

November 12, 2021

Here are seven top growth stocks investors may want to consider when looking at options in this hyper-growth market right now.

Via InvestorPlace

86 Biggest Movers From Yesterday ↗

November 04, 2021

Gainers FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million....

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.